Recomendações na Abordagem do Doente com Hidradenite Supurativa
DOI:
https://doi.org/10.20344/amp.18916Palavras-chave:
Hidradenite Supurativa/cirurgia, Hidradenite Supurativa/diagnóstico, Hidradenite Supurativa/tratamentoResumo
A hidradenite supurativa é uma dermatose inflamatória crónica e recorrente que se caracteriza pela presença de nódulos inflamatórios e abcessos nas áreas ricas em glândulas apócrinas, que podem evoluir para fístulas supurativas e cicatrizes. Apesar de ser considerada uma das patologias dermatológicas com maior impacto na qualidade de vida dos doentes, é frequentemente subdiagnosticada. A hidradenite supurativa, sobretudo nas suas formas mais graves, associa-se a diversas comorbilidades, pelo que é fundamental adotar uma perspetiva holística e multidisciplinar na gestão destes doentes. A abordagem terapêutica é complexa e desafiante. A terapêutica médica é multifacetada e deve ser adaptada à apresentação clínica e gravidade da doença. A terapêutica cirúrgica deverá ser equacionada como adjuvante à terapêutica médica, em particular nos casos refratários e perante cicatrizes ou mutilação anatómica e/ou funcional. As presentes recomendações pretendem reunir os principais aspetos da abordagem ao doente com hidradenite supurativa e destinam-se a todos os profissionais de saúde envolvidos no seu acompanhamento.
Downloads
Referências
Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos-Bourboulis EJ, Fabbrocini G, et al. What causes hidradenitis suppurativa? - 15 years after. Exp Dermatol. 2020;29:1154–70. DOI: https://doi.org/10.1111/exd.14214
Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–44. DOI: https://doi.org/10.1111/jdv.12966
Revuz JE, Jemec GB. Diagnosing hidradenitis suppurativa. Dermatol Clin. 2016;34:1–5. DOI: https://doi.org/10.1016/j.det.2015.08.009
Sabat R, Jemec GB, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18. DOI: https://doi.org/10.1038/s41572-020-0149-1
Matusiak Ł, Bieniek A, Szepietowski JC. Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol. 2009;61:362–5. DOI: https://doi.org/10.1016/j.jaad.2009.03.043
Smith MK, Nicholson CL, Parks-Miller A, Hamzavi IH. Hidradenitis suppurativa: an update on connecting the tracts. F1000Res. 2017;6:1272. DOI: https://doi.org/10.12688/f1000research.11337.1
Hoffman L, Ghias M, Lowes M. Pathophysiology of hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36:47–54. DOI: https://doi.org/10.12788/j.sder.2017.017
Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GB, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82:366–76. DOI: https://doi.org/10.1016/j.jaad.2019.06.1301
Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997–1035. DOI: https://doi.org/10.1111/j.1365-2133.2008.08832.x
Nguyen TV, Damiani G, Orenstein LA, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35:50–61. DOI: https://doi.org/10.1111/jdv.16677
Balieva F, Kupfer J, Lien L, Gieler U, Finlay AY, Tomás-Aragonés L, et al. The burden of common skin diseases assessed with the EQ5DTM: a European multicentre study in 13 countries. Br J Dermatol. 2017;176:1170–8. DOI: https://doi.org/10.1111/bjd.15280
Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J. Impact of hidradenitis suppurativa on work loss, indirect costs and income. Br J Dermatol. 2019;181:147–54. DOI: https://doi.org/10.1111/bjd.17101
Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546–9. DOI: https://doi.org/10.1111/bjd.14038
Loget J, Saint-Martin C, Guillem P, Kanagaratnam L, Becherel PA, Nassif A, et al. Errance médicale des patients atteints d’hidradénite suppurée: un problème majeur et persistant. Étude « R-ENS Verneuil ». Ann Dermatol Venereol. 2018;145:331–8. DOI: https://doi.org/10.1016/j.annder.2018.01.043
Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology. 2020;236:421–30. DOI: https://doi.org/10.1159/000508787
Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, et al. Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study*. Br J Dermatol. 2021;184:133–40. DOI: https://doi.org/10.1111/bjd.18983
Martorell A, Caballero A, González Lama Y, Jiménez-Gallo D, Lázaro Serrano M, Miranda J, et al. Manejo del paciente con hidradenitis supurativa. Actas Dermosifiliogr. 2016;107:32–42. DOI: https://doi.org/10.1016/S0001-7310(17)30007-8
Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T. Evidencebased approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17:343–51. DOI: https://doi.org/10.1007/s11154-016-9328-5
Dauden E, Lazaro P, Aguilar MD, Blasco AJ, Suarez C, Marin I, et al. Recommendations for the management of comorbidity in hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2018;32:129–44. DOI: https://doi.org/10.1111/jdv.14517
Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, et al. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86:1092–101. DOI: https://doi.org/10.1016/j.jaad.2021.01.059
Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33:19–31. DOI: https://doi.org/10.1111/jdv.15233
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2019;81:91–101. DOI: https://doi.org/10.1016/j.jaad.2019.02.068
Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019;180:1009–17. DOI: https://doi.org/10.1111/bjd.17537
Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart C, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2019;81:76–90. DOI: https://doi.org/10.1016/j.jaad.2019.02.067
Bassas-Vila J, González Lama Y. Hidradenitis supurativa y enfermedad de Crohn perianal: diagnóstico diferencial. Actas Dermosifiliogr. 2016;107:27–31. DOI: https://doi.org/10.1016/S0001-7310(17)30006-6
Savage KT, Singh V, Patel ZS, Yannuzzi CA, McKenzie-Brown AM, Lowes MA, et al. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol. 2021;85:187–99. DOI: https://doi.org/10.1016/j.jaad.2020.09.039
Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GB, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177:1401–9. DOI: https://doi.org/10.1111/bjd.15748
Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171:1434–42. DOI: https://doi.org/10.1111/bjd.13270
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6. DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x
Direção-Geral da Saúde. A dor como 5o sinal vital. Registo sistemático da intensidade da dor. Circular normativa: Ministério da Saúde No09/DGCG de 2003. Lisboa: DGS; 2003.
Martorell A, Segura Palacios JM. Ecografía de la hidradenitis supurativa. Actas Dermosifiliogr. 2015;106:S49–59. DOI: https://doi.org/10.1016/S0001-7310(16)30007-2
Martorell A, Alfageme Roldán F, Vilarrasa Rull E, Ruiz-Villaverde R, Romaní De Gabriel J, García Martínez F, et al. Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study. J Eur Acad Dermatol Venereol. 2019;33:2137-42. DOI: https://doi.org/10.1111/jdv.15710
Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A comparison of international management guidelines for hidradenitis suppurativa. Dermatology. 2021;237:81–96. DOI: https://doi.org/10.1159/000503605
Orenstein LA, Nguyen TV, Damiani G, Sayed C, Jemec GB, Hamzavi I. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology. 2020;236:393–412. DOI: https://doi.org/10.1159/000507323
Molinelli E, Brisigotti V, Simonetti O, Campanati A, Sapigni C, D’Agostino GM, et al. Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance. Br J Dermatol. 2020;183:1117–9. DOI: https://doi.org/10.1111/bjd.19337
van Straalen KR, Tzellos T, Guillem P, Benhadou F, Cuenca-Barrales C, Daxhelet M, et al. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study. J Am Acad Dermatol. 2021;85:369–78. DOI: https://doi.org/10.1016/j.jaad.2020.12.089
Marasca C, Tranchini P, Marino V, Annunziata MC, Napolitano M, Fattore D, et al. The pharmacology of antibiotic therapy in hidradenitis suppurativa. Expert Rev Clin Pharmacol. 2020;13:521–30. DOI: https://doi.org/10.1080/17512433.2020.1762571
Delaunay J, Villani AP, Guillem P, Tristan A, Boibieux A, Jullien D. Oral ofloxacin and clindamycin as an alternative to the classic rifampicin–clindamycin in hidradenitis suppurativa: retrospective analysis of 65 patients. Br J Dermatol. 2018;178:e15–6. DOI: https://doi.org/10.1111/bjd.15739
Rabindranathnambi A, Jeevankumar B. Dapsone in hidradenitis suppurativa: a systematic review. Dermatol Ther. 2022;12:285–93. DOI: https://doi.org/10.1007/s13555-021-00674-x
Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa. J Am Acad Dermatol. 2020;82:1061–82. DOI: https://doi.org/10.1016/j.jaad.2019.08.089
Poli F, Revuz J. «Poussées inflammatoires d’acné» sous isotrétinoïne révélant une hidradénite suppurée: 4 cas. Ann Dermatol Venereol. 2019;146:4–8. DOI: https://doi.org/10.1016/j.annder.2018.07.020
Choi E, Ooi XT, Chandran NS. Hidradenitis suppurativa in pediatric patients. J Am Acad Dermatol. 2022;86:140–7. DOI: https://doi.org/10.1016/j.jaad.2020.08.045
Chellappan B, Nguyen DD, Hoyer P, Ross L. Dermatologic management of hidradenitis suppurativa and impact on pregnancy and breastfeeding. Cutis. 2022;109:160–2. DOI: https://doi.org/10.12788/cutis.0480
Bechara FG, Hessam S. Hidradenitis suppurativa. MMW Fortschr Med. 2016;158:52–3. DOI: https://doi.org/10.1007/s15006-016-8662-6
Shanmugam VK, Mulani S, McNish S, Harris S, Buescher T, Amdur R. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy. Int J Dermatol. 2018;57:62–9. DOI: https://doi.org/10.1111/ijd.13798
Downloads
Publicado
Como Citar
Edição
Secção
Licença
Direitos de Autor (c) 2023 Acta Médica Portuguesa
Este trabalho encontra-se publicado com a Creative Commons Atribuição-NãoComercial 4.0.
Todos os artigos publicados na AMP são de acesso aberto e cumprem os requisitos das agências de financiamento ou instituições académicas. Relativamente à utilização por terceiros a AMP rege-se pelos termos da licença Creative Commons ‘Atribuição – Uso Não-Comercial – (CC-BY-NC)’.
É da responsabilidade do autor obter permissão para reproduzir figuras, tabelas, etc., de outras publicações. Após a aceitação de um artigo, os autores serão convidados a preencher uma “Declaração de Responsabilidade Autoral e Partilha de Direitos de Autor “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) e a “Declaração de Potenciais Conflitos de Interesse” (http://www.icmje.org/conflicts-of-interest) do ICMJE. Será enviado um e-mail ao autor correspondente, confirmando a receção do manuscrito.
Após a publicação, os autores ficam autorizados a disponibilizar os seus artigos em repositórios das suas instituições de origem, desde que mencionem sempre onde foram publicados e de acordo com a licença Creative Commons
